Volume | 102,841 |
|
|||||
News | - | ||||||
Day High | 11.70 | Low High |
|||||
Day Low | 11.23 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pulse Biosciences Inc | PLSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.70 | 11.23 | 11.70 | 11.40 | 11.85 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,693 | 102,841 | $ 11.48 | $ 1,180,627 | - | 3.78 - 14.96 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:28:14 | 1 | $ 11.40 | USD |
Pulse Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
625.8M | 54.99M | - | 0 | -42.21M | -0.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pulse Biosciences News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.06 | 14.40 | 11.23 | 12.86 | 184,230 | -0.66 | -5.47% |
1 Month | 8.57 | 14.96 | 8.57 | 12.61 | 315,005 | 2.83 | 33.02% |
3 Months | 8.57 | 14.96 | 6.595 | 9.89 | 225,926 | 2.83 | 33.02% |
6 Months | 9.84 | 14.96 | 6.595 | 10.01 | 221,677 | 1.56 | 15.85% |
1 Year | 6.37 | 14.96 | 3.78 | 8.42 | 215,809 | 5.03 | 78.96% |
3 Years | 17.06 | 29.16 | 1.18 | 7.29 | 162,745 | -5.66 | -33.18% |
5 Years | 12.57 | 45.82 | 1.18 | 9.79 | 133,344 | -1.17 | -9.31% |
Pulse Biosciences Description
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. |